{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:56:17Z","timestamp":1778806577582,"version":"3.51.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia","doi-asserted-by":"publisher","award":["2021LHMS08019"],"award-info":[{"award-number":["2021LHMS08019"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Adoptive transfer of natural killer (NK) cells represents a viable treatment method for patients with advanced malignancies. Our team previously developed a simple, safe, and cost-effective method for obtaining high yields of pure and functional NK cells from cord blood (CB) without the need for cell sorting, feeder cells, or multiple cytokines. We present the case of a 52-year-old female patient diagnosed with poorly differentiated stage IVB (T3N2M1) endometrial cancer, who exhibited leukemoid reaction and pretreatment thrombocytosis as paraneoplastic syndromes. The patient received two courses of CB-derived NK (CB-NK) cell immunotherapy between March and September 2022, due to her extremely low NK cell activity. Two available CB units matched at 8\/10 HLA with KIR-mismatch were chosen, and we were able to produce NK cells with high yield (&amp;gt;1.0\u00d710<jats:sup>10<\/jats:sup> NK cells), purity (&amp;gt;90%), and function (&amp;gt;80%) from CB without cell sorting, feeder cells, or multiple cytokines. These cells were then adoptively transferred to the patient. No adverse effects or graft-versus-host disease were observed after infusion of CB-NK cells. Our clinical experience supports the efficacy of CB-NK cell treatment in increasing NK cell activity, depleting tumor activity, improving quality of life, and reducing the size of abdominal and pelvic masses with the disappearance of multiple lymph node metastases through the regulation of systemic antitumor immunity. Remarkably, the white blood cell and platelet counts decreased to normal levels after CB-NK cell immunotherapy. This clinical work suggests that CB-NK cell immunotherapy holds promise as a therapeutic approach for endometrial cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1213161","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T16:23:51Z","timestamp":1688142231000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: Cord blood-derived natural killer cells as new potential immunotherapy drug for solid tumor: a case study for endometrial cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Yongxu","family":"Mu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabei","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"BSR20202321","DOI":"10.1042\/BSR20202321","article-title":"The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer","volume":"41","author":"Liu","year":"2021","journal-title":"Biosci Rep 41"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12672-022-00466-5","article-title":"The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H\/MMR-D endometrial carcinomas","volume":"13","author":"Guo","year":"2022","journal-title":"Discov Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00877","article-title":"And resident NK cell phenotype and function","volume":"10","author":"Degos","year":"2019","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u201cOff-The-Shelf\u201d allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584099","article-title":"Cord-blood natural killer cell-based immunotherapy for cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.3390\/cancers14184439","article-title":"Cord blood-derived natural killer cell exploitation in immunotherapy protocols: more than a promise","volume":"14","author":"Damele","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B8","first-page":"80","volume-title":"A simple method for in vitro preparation of natural killer cells from cord blood. BMC Biotechnol","author":"Mu","year":"2019"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-018-0213-2","article-title":"Zoledronate increases enrichment, activation and expansion of natural killer cells from umbilical cord blood","volume":"31","author":"Ma","year":"2018","journal-title":"Hum Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.12.002","article-title":"Generating natural killer cells for adoptive transfer: expanding horizons","volume":"23","author":"Kundu","year":"2021","journal-title":"Cytotherapy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1115178","DOI":"10.1080\/2162402X.2015.1115178","article-title":"Advances in clinical NK cell studies: donor selection, manufacturing and quality control","volume":"5","author":"Koehl","year":"2016","journal-title":"Oncoimmunology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/ijms18071600","article-title":"The effects of artemisinin on the cytolytic activity of natural killer (NK) cells","volume":"18","author":"Houh","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"368504211004028","DOI":"10.1177\/00368504211004028","article-title":"The co-occurrence of leukemoid reaction and hypercalcemia in a patient with endometrial cancer: a case report and literature review","volume":"104","author":"Tao","year":"2021","journal-title":"Sci Prog"},{"key":"B14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1186\/1471-2407-14-670","article-title":"Leukemoid reaction in cervical cancer: a case report and review of the literature","volume":"14","author":"Qing","year":"2014","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12885-018-5264-y","article-title":"Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis","volume":"19","author":"Nie","year":"2019","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302517","article-title":"Donor killer cell ig-like receptor b haplotypes, recipient HLA-C1, and HLA-c mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia","volume":"192","author":"Cooley","year":"2014","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0039","article-title":"Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immunotherapy","volume":"13","author":"Wang","year":"2017","journal-title":"Future Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15265","article-title":"Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma","volume":"36","author":"Lee","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26636","article-title":"Changes in natural killer cell activity after surgery and predictors of its recovery-failure","volume":"124","author":"Kim","year":"2021","journal-title":"J Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03035-x","article-title":"Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab","volume":"71","author":"Cho","year":"2022","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S344707","article-title":"Progression-free survival of a patient with advanced hepatocellular carcinoma treated with adoptive cell therapy using natural killer cells: a case report","volume":"15","author":"Hong","year":"2022","journal-title":"OncoTargets Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1213161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T16:23:56Z","timestamp":1688142236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1213161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2023.1213161"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1213161","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"article-number":"1213161"}}